

Chiara Bortolaschi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2775276/publications.pdf>

Version: 2024-02-01

53
papers

1,213
citations

394421

19
h-index

414414

32
g-index

54
all docs

54
docs citations

54
times ranked

2131
citing authors

#	ARTICLE	IF	CITATIONS
1	Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 67-77.	2.6	11
2	Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110481.	4.8	6
3	Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia. <i>Molecular Neurobiology</i> , 2022, 59, 3485-3503.	4.0	19
4	Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder. <i>Frontiers in Pharmacology</i> , 2022, 13, 873271.	3.5	7
5	Common effects of bipolar disorder medications on expression quantitative trait loci genes. <i>Journal of Psychiatric Research</i> , 2022, 150, 105-112.	3.1	2
6	Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression. <i>Acta Neuropsychiatrica</i> , 2022, 34, 220-227.	2.1	7
7	Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7180.	4.1	8
8	Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7508.	4.1	2
9	Effects of psychoactive drugs on cellular bioenergetic pathways. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 79-93.	2.6	5
10	Systemic inflammation and grey matter volume in schizophrenia and bipolar disorder: Moderation by childhood trauma severity. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110013.	4.8	23
11	Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 120, 537-541.	6.1	42
12	Preventing the development of severe COVID-19 by modifying immunothrombosis. <i>Life Sciences</i> , 2021, 264, 118617.	4.3	40
13	Association between serum interleukin-6 and frailty in older men: cross-sectional data. <i>European Geriatric Medicine</i> , 2021, 12, 887-892.	2.8	7
14	The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 244-263.	6.1	29
15	Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7164.	4.1	11
16	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. <i>Cytokine</i> , 2021, 144, 155593.	3.2	61
17	The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. <i>Pharmacological Research</i> , 2021, 170, 105729.	7.1	24
18	Polyphenols as adjunctive treatments in psychiatric and neurodegenerative disorders: Efficacy, mechanisms of action, and factors influencing inter-individual response. <i>Free Radical Biology and Medicine</i> , 2021, 172, 101-122.	2.9	19

#	ARTICLE	IF	CITATIONS
19	Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. <i>Journal of Clinical Medicine</i> , 2021, 10, 4095.	2.4	8
20	Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial. <i>Journal of Psychiatric Research</i> , 2021, 142, 376-383.	3.1	1
21	A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. <i>European Neuropsychopharmacology</i> , 2021, 53, 120-126.	0.7	0
22	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 775-783.	2.6	27
23	Drugs used to treat bipolar disorder act via microRNAs to regulate expression of genes involved in neurite outgrowth. <i>Journal of Psychopharmacology</i> , 2020, 34, 370-379.	4.0	15
24	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <i>Life Sciences</i> , 2020, 262, 118541.	4.3	12
25	Transcriptional Effects of Psychoactive Drugs on Genes Involved in Neurogenesis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8333.	4.1	7
26	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. <i>Life Sciences</i> , 2020, 258, 118166.	4.3	79
27	Total Antioxidant Capacity and Frailty in Older Men. <i>American Journal of Men's Health</i> , 2020, 14, 155798832094659.	1.6	8
28	Interleukin-6 and total antioxidant capacity levels following N-acetylcysteine and a combination nutraceutical intervention in a randomised controlled trial for bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2020, 32, 313-320.	2.1	3
29	Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e035080.	1.9	1
30	The compensatory antioxidant response system with a focus on neuroprogressive disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109708.	4.8	19
31	Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis – A possible therapeutic mechanism. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 766-777.	2.6	5
32	N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 555.	1.6	8
33	Shared pathways for neuroprogression and somatoprogession in neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 862-882.	6.1	74
34	The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. <i>Frontiers in Psychiatry</i> , 2019, 10, 115.	2.6	16
35	Association between childhood trauma exposure and pro-inflammatory cytokines in schizophrenia and bipolar-I disorder. <i>Psychological Medicine</i> , 2019, 49, 2736-2744.	4.5	22
36	Mechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 582-591.	2.1	19

#	ARTICLE	IF	CITATIONS
37	Mediator effects of parameters of inflammation and neurogenesis from a <i>N</i>-acetyl cysteine clinical-trial for bipolar depression. <i>Acta Neuropsychiatrica</i> , 2018, 30, 334-341.	2.1	16
38	A review of the neurobiological underpinning of comorbid substance use and mood disorders. <i>Journal of Affective Disorders</i> , 2018, 241, 388-401.	4.1	33
39	First-Episode Schizophrenia and Diabetes Risk. <i>JAMA Psychiatry</i> , 2017, 74, 761.	11.0	1
40	Adjunctive <i>N</i>-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. <i>Acta Neuropsychiatrica</i> , 2017, 29, 337-346.	2.1	25
41	Oxidative and nitrosative stress biomarkers in chronic schizophrenia. <i>Psychiatry Research</i> , 2017, 253, 43-48.	3.3	43
42	Parkinson's Disease is Accompanied by Intertwined Alterations in Iron Metabolism and Activated Immune-inflammatory and Oxidative Stress Pathways. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 484-491.	1.4	25
43	Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson's disease and its progression: Disease and staging biomarkers and new drug targets. <i>Neuroscience Letters</i> , 2016, 617, 66-71.	2.1	91
44	Are PTH levels related to oxidative stress and inflammation in chronic kidney disease patients on hemodialysis?. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2016, 38, 288-295.	0.9	13
45	Association of paraoxonase (PON)1 activity, glutathione S-transferase GST T1/M1 and STin.2 polymorphisms with comorbidity of tobacco use disorder and mood disorders. <i>Neuroscience Letters</i> , 2015, 585, 132-137.	2.1	14
46	Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome and tobacco use disorder. <i>Journal of Affective Disorders</i> , 2015, 179, 148-155.	4.1	27
47	Passiflora incarnata treatment during gestation and lactation: toxicological and antioxidant evaluation in wistar dams. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 2014, 50, 353-359.	1.2	3
48	Paraoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity. <i>Redox Report</i> , 2014, 19, 232-241.	4.5	7
49	Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism'smoking interactions differentially predict the odds of major depression and bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 159, 23-30.	4.1	68
50	Paraoxonase 1 status and interactions between Q192R functional genotypes by smoking contribute significantly to total plasma radical trapping antioxidant potential. <i>Neuroscience Letters</i> , 2014, 581, 46-51.	2.1	6
51	Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. <i>Neuroscience Letters</i> , 2013, 544, 136-140.	2.1	87
52	Increased oxidative stress in foam cells obtained from hemodialysis patients. <i>Hemodialysis International</i> , 2013, 17, 266-274.	0.9	5
53	Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. <i>Journal of Affective Disorders</i> , 2013, 150, 923-930.	4.1	101